Emerging evidence revealed that METTL3-induced m6A modification played an important role in acquired resistance to tyrosine kinase inhibitors in leukemia cells [26], PLX4032 resistance in melanoma [27], and cisplatin resistance in epithelial ovarian cancer [28]. The gene discussed is METTL3; the disease is melanoma.